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Abstract Alpha-adrenoceptors in the nucleus accumbens
are known to inhibit accumbal dopamine release from
reserpine-sensitive pools. The aim of this study was to test
our previously reported hypothesis that accumbal noradren-
aline that controls the dopamine release from these storage
vesicles is derived from alpha-methyl-para-tyrosine-sensitive
pools. The sensitivity of accumbal alpha-adrenoceptors to
noradrenergic agents depends on the amount of noradrena-
line that is available in the synapse. In case the synaptic
noradrenaline levels decrease, the conformation of alpha-
adrenoceptors changes into a state that makes these receptors
more sensitive to its agonists. The effects of alpha-methyl-
para-tyrosine, respectively reserpine, on the alpha-adreno-
ceptor-agonist-induced changes of accumbal dopamine
release were investigated. Alpha-methyl-para-tyrosine,
but not reserpine, made accumbal postsynaptic alpha-
adrenoceptors more sensitive to phenylephrine. These results
indicate that noradrenaline that inhibits the release of
dopamine from reserpine-sensitive storage vesicles, via
stimulation of accumbal postsynaptic alpha-adrenoceptors, is
derived from alpha-methyl-para-tyrosine-sensitive pools.
The clinical impact of these data is discussed.
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Introduction
It has been found that the sensitivity of alpha-adrenocep-
tors to noradrenergic agents depends on the amount of
noradrenaline that is available in the synapse. In case the
synaptic noradrenaline levels increase, the conformation of
alpha-adrenoceptors change into a state that makes them
less sensitive to agonists and more sensitive to antagonists
(Cools et al. 1987, 1991; Tuinstra and Cools 2000a; Cools
and Tuinstra 2003; Aono et al. 2007). The opposite holds
also true: in case the synaptic noradrenaline levels
decrease the conformation of alpha-adrenoceptors change
into a state that makes them more sensitive to agonists and
less sensitive to antagonists (Cools et al. 1987, 1991;
Tuinstra and Cools 2000a; Cools and Tuinstra 2003). It is
evident that these processes provide a homeostatic mech-
anism, controlling the adrenergic activity at postsynaptic
receptors.
Alpha-adrenoceptors are known to control the release
of dopamine. Both in vitro and in vivo experiments have
revealed that stimulation of postsynaptic alpha-adreno-
ceptors that are located on dopaminergic neurons inhibits
the release of dopamine in the nucleus accumbens,
whereas inhibition of these receptors stimulates the
release of dopamine in this brain structure (Nurse et al.
1984, 1985; Russell et al. 1988, 1993; Tuinstra and Cools
2000a; Cools and Tuinstra 2003; see also Verheij and
Cools 2008). It is generally accepted that presynaptic
alpha-adrenoceptors regulate the amount of noradrenaline
in the synapse and, accordingly, regulate the amount
of noradrenaline at the level of postsynaptic alpha-
adrenoceptors. Interestingly, the noradrenaline agonist
phenylephrine (PE) has been found to act at accumbal
presynaptic, but not postsynaptic, alpha-adrenoceptors
of otherwise untreated rats (Tuinstra and Cools 2000a,
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2000b; Cools and Tuinstra 2003; Aono et al. 2007; see
also below). This action of PE has been found to reduce
the synaptic noradrenaline levels (Aono et al. 2007),
which, in turn, results in an increased release of accumbal
dopamine in these rats (Tuinstra and Cools 2000a, 2000b;
Cools and Tuinstra 2003). It has recently been demon-
strated that the alpha-adrenoceptor-mediated release of
accumbal dopamine is not derived from alpha-methyl-
para-tyrosine (AMPT)-sensitive dopamine pools (Tuinstra
and Cools 2000b; see also Verheij and Cools 2008). In
fact, the alpha-adrenoceptor-mediated dopamine release is
derived from reserpine (RES)-sensitive pools of dopamine
(Cools and Verheij 2002; Verheij and Cools submitted;
see also Verheij and Cools 2008). It is currently unknown
which type of noradrenergic pool releases noradrenaline
that inhibits accumbal dopamine release from these
storage pools. On the basis of previously reported neu-
rochemical data, however, it has been hypothesized that
accumbal noradrenaline derived from AMPT-sensitive
pools controls the alpha-adrenoceptor-mediated release of
accumbal dopamine from RES-sensitive vesicles (Saigusa
et al. 1999).
Given the fact that stimulation of postsynaptic alpha-
adrenoceptors in the nucleus accumbens inhibits the
release of accumbal dopamine (see above), the inability
of the alpha-adrenoceptor agonist PE to decrease the
amount of accumbal dopamine in otherwise untreated rats
(Tuinstra and Cools 2000a, 2000b; see also above) has
been ascribed to the presence of a relatively high amount
of noradrenaline in the synapses of these rats (Tuinstra
and Cools 2000a). Under these conditions it can be
predicted that an experimentally induced decrease of the
amount of synaptic noradrenaline makes the accumbal
postsynaptic alpha-adrenoceptors sensitive to PE. AMPT
is known to reduce the alpha-adrenoceptor-mediated
release of noradrenaline (Brannan et al. 1991; McTavish
et al. 1999).
In order to test whether the noradrenaline release at the
level of postsynaptic alpha-adrenoceptors in the nucleus
accumbens is derived from AMPT-sensitive pools, the
effects of AMPT on the PE-induced accumbal dopamine
release were established. Combining the above-mentioned
considerations results in the hypothesis that AMPT makes
the accumbal postsynaptic alpha-adrenoceptors sensitive
to PE. It is hypothesized that PE decreases the amount of
accumbal dopamine in AMPT-treated rats (postsynaptic
action) in contrast to PE that will increase the amount of
accumbal dopamine in control rats (presynaptic action). In
order to establish whether RES-sensitive pools contribute
to the release of accumbal noradrenaline at postsyn-
aptic alpha-adrenoceptors as well, the effects of RES
on the PE-induced accumbal dopamine release were also
investigated.
Materials and methods
Rats were unilaterally implanted with a guide cannula
directed at the right nucleus accumbens (for procedures see
Verheij and Cools 2007). The rats were allowed to recover
from surgery for the next 7–10 days in dialysis cages. At
3 days prior to the start of the experiment, each rat was
gently picked up (three times per day) in order to habituate
to the procedure assessed on the day when accumbal
dopamine was measured. At the start of the experiment, a
dialysis probe was connected to a swivel and accumbal
dialysates were analyzed for dopamine according to pre-
viously described procedures (see Verheij and Cools 2007).
The probes had an in vitro recovery of 10–12% for dopa-
mine (Verheij and Cools 2007). The dopamine sensitivity
was 500 fg per sample (Verheij and Cools 2007). This
sensitivity has repeatedly been shown to be sufficient for
detecting the currently observed changes in the amount of
dopamine (De Leonibus et al. 2006; Verheij and Cools
2007; Verheij et al. 2008).
As soon as the dopamine samples differed less than
10%, three baseline samples were taken and one group of
rats was treated with 0.1 mM (2 ll/min for 40 min, intra-
accumbens) of AMPT or its solvent (Ringer), whereas
another group of rats was treated with 1 mg/kg (1 ml/kg,
i.p.) of RES or its solvent (pH = 2.4). At 40 and 100 min
after AMPT or its solvent and at 24 h after RES or its
solvent, rats were subjected to a 40 min lasting intra-ac-
cumbens infusion of 0.01 mM (2 ll/min) of the alpha-1
adrenoceptor agonist PE.
The AMPT- and RES-induced changes of accumbal
dopamine over time have already been published elsewhere
(time effects of AMPT: Tuinstra and Cools 2000b; time
effects of RES: Verheij and Cools 2007). The dopamine
decreasing effects of these agents were found to be maxi-
mal and stable throughout the period that PE was given
(see Tuinstra and Cools 2000b and Verheij and Cools
2007). Modified Ringer solution served as control for PE.
At the end of the microdialysis experiments, rats were
given an overdose of pentobarbital and were intracardially
perfused with paraformaldehyde. Vibratome sections were
cut to verify the location of the microdialysis probe.
It is important to realize that one can only measure a PE-
induced increase of accumbal dopamine under the condition
that the presynaptic pools of dopamine are not empty. For
this reason, experiments were performed in high responders
to novelty (HR) that were selected from the Nijmegen out-
bred strain of Wistar rats (Cools et al. 1990). It has
previously been reported that an environmental or phar-
macological challenge could still increase accumbal
dopamine levels in these animals after the chosen treatment
with AMPT (see Saigusa et al. 1999) or RES (see Verheij
et al. 2008). HR were selected on the basis of their
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locomotor response to a novel open field and defined as
animals that travelled more than 6,000 cm in 30 min and
habituated (no locomotor activity for a period of at least
90 s) after 840 s (Verheij and Cools 2007). All experiments
were performed in accordance with institutional, national
and international guidelines on animal care and welfare.
Data were statistically analyzed using a two-way ANOVA
with the factors treatment and time (for repeated measures).
Post hoc t tests were performed where appropriate. All
values are expressed as mean ± SEM.
Results
As much as 37% of the selected rats fulfilled the criteria for
HR (n = 61). The average distance travelled on the open-
field was 8.976 ± 261 cm in 30 min. The average habitua-
tion time of the animals was 1.384 ± 48 s. Representative
placements of the dialysis probes are depicted in Fig. 1 (in-
teraural level: 10.20 mm). Probes were found between
interaural levels 10.2 and 11.2 mm (Paxinos and Watson
1986; Verheij and Cools 2007). Only data of rats with cor-
rectly placed probes were incorporated in the study (n = 59).
Basal levels of dopamine were 3.8 ± 0.5 pg/20 min in HR
treated with the solvent of AMPT (Ringer). The dose of
0.1 mM of AMPT reduced these levels of dopamine to
79 ± 3.1% at t = 40 min and to 81 ± 5.9% at t = 100 min
(one sample t test, 40 min: t(7) = -6.840, P B 0.001;
100 min: t(7) = -3.209, P = 0.015; reductions similar to
Tuinstra and Cools 2000b). The basal levels of dopamine
were 2.9 ± 0.33 pg/20 min in HR treated with the solvent of
RES. The basal concentration of dopamine did not differ
between rats that were treated with the solvent of AMPT or
the solvent of RES (Student’s t test: ns). The dose of 1 mg/kg
of RES reduced the basal levels of dopamine to 56 ± 8.3% at
24 h (one sample t test, 24 h: t(17) = -5.277, P B 0.001;
reduction similar to Verheij and Cools 2007).
The dose of 0.01 mM of PE increased accumbal dopa-
mine levels in rats treated with the solvent of AMPT
(Fig. 2; one-way ANOVA, time effect: F(7,56) = 6.433,
P B 0.001) and in rats treated with the solvent of RES
(Fig. 2; one-way ANOVA, time effect: F(7,49) = 9.521,
P B 0.001). The PE-induced increase of dopamine did not
differ between the two groups of rats (Fig. 2; two-way
ANOVA, treatment (9time) effect: ns). PE decreased
dopamine levels in rats that were treated with AMPT
40 min earlier (Fig. 3a; two-way ANOVA, treat-
ment 9 time effect: F(5,70) = 3.688, P = 0.005) and
increased dopamine levels in rats that were treated with
AMPT 100 min earlier (Fig. 3b; two-way ANOVA, treat-
ment 9 time effect: F(5,70) = 10.496, P B 0.001). The PE-
induced dopamine increase in the latter group of AMPT-
treated rats was equal to the PE-induced dopamine increase
that was observed in the control rats treated with the sol-
vent of AMPT (Fig. 3b versus Fig. 2; two-way ANOVA,
treatment (9time) effect: ns). PE increased dopamine
levels in rats that were treated with RES 24 h earlier
(Fig. 4; two-way ANOVA, treatment 9 time effect:
F(5,80) = 8.964, P B 0.001). The PE-induced dopamine
increase in these RES-treated rats was equal to the PE-
induced dopamine increase that was observed in the control
rats treated with the solvent of RES (Fig. 4 versus Fig. 2;
two-way ANOVA, treatment (9time) effect: ns).
Fig. 1 Three unilateral microdialysis probe tracks located in the right
nucleus accumbens (see also Verheij and Cools 2007). The probe
protrudes 2 mm below the distal end of the guide cannula. The brain
region in which correctly placed probes were found is indicated in
gray. IA corresponds to the distance (mm) from the interaural line
according to Paxinos and Watson (1986). NAC nucleus accumbens,
CPU caudate putamen, CC corpus callosum
Fig. 2 Effects of intra-accumbens infusion of 0.01 mM of the alpha-
adrenoceptor agonist phenylephrine in rats treated with the solvent of
either alpha-methyl-para-tyrosine (filled symbols) or reserpine (open
symbols). Phenylephrine increased accumbal dopamine levels in these
control rats. The black line represents the infusion time of phenyl-
ephrine (40 min). *Significant increase relative to the baseline (one
sample t tests)
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Discussion
The AMPT-induced changes in the baseline levels of ac-
cumbal dopamine at 40 and 100 min after its
administration are very similar to our previously reported
AMPT-induced changes in accumbal dopamine (Tuinstra
and Cools 2000b). The same holds true for the RES-
induced changes in the baseline levels of accumbal dopa-
mine at 24 h after its administration (Verheij and Cools
2007). Our previous studies have shown no signs of an
increased synthesis of dopamine at 40 min after AMPT or
at 24 h after RES.
The alpha-1 adrenoceptor agonist PE (Ruffolo and
Hieble 1994) strongly increased accumbal dopamine levels
in control rats (Fig. 2), confirming the outcome of our
previous studies that PE acts at presynaptic alpha-adreno-
ceptors in the nucleus accumbens of otherwise untreated
rats (Tuinstra and Cools 2000a; Cools and Tuinstra 2003;
Aono et al. 2007). In contrast, PE decreased accumbal
dopamine levels in rats that were treated with AMPT
40 min earlier (Fig. 3a). The possibility that PE did not
increase dopamine release because the AMPT-sensitive
dopamine pools of these rats were empty can be rejected
since alpha-adrenoceptors do not control the release of
dopamine from this type of pool (Tuinstra and Cools
2000b; see also Verheij and Cools 2008). The present
finding that PE reduced dopamine levels in HR treated with
AMPT, therefore, demonstrates that this agonist stimulates
postsynaptic alpha-adrenoceptors in these rats. This finding
is in line with the fact that stimulation of accumbal post-
synaptic alpha-adrenoceptors inhibits the release of
dopamine from RES-sensitive pools (see ‘‘Introduction’’).
Furthermore, these data confirm our hypothesis that AMPT
increases the sensitivity of accumbal postsynaptic alpha-
adrenoceptors (see ‘‘Introduction’’). The present study
shows that noradrenaline that regulates the dopamine
derived from RES-sensitive vesicles is derived from
AMPT-sensitive pools. The finding that the PE-induced
decrease of dopamine seen in rats treated 40 min earlier
with AMPT (Fig. 3a) was replaced by a PE-induced
increase of dopamine in rats treated 100 min earlier with
AMPT (Fig. 3b) illustrates that the ability of AMPT to
change the state of the alpha-adrenoceptors in the nucleus
accumbens was time-dependent and reversible.
Fig. 3 a Effects of intra-accumbens infusion of 0.01 mM of the
alpha-adrenoceptor agonist phenylephrine at 40 min after 0.1 mM of
alpha-methyl-para-tyrosine. Phenylephrine decreased accumbal dopa-
mine levels 40 min after alpha-methyl-para-tyrosine. The black line
represents the infusion time of phenylephrine (40 min). *Significant
decrease compared to control (Student’s t tests). b Effects of intra-
accumbens infusion of 0.01 mM of the alpha-adrenoceptor agonist
phenylephrine at 100 min after 0.1 mM of alpha-methyl-para-tyro-
sine. Phenylephrine increased accumbal dopamine levels 100 min
after alpha-methyl-para-tyrosine. The black line represents the
infusion time of phenylephrine (40 min). *Significant increase
compared to control (Student’s t tests)
Fig. 4 Effects of intra-accumbens infusion of 0.01 mM of the alpha-
adrenoceptor agonist phenylephrine at 24 h after 1 mg/kg of reser-
pine. Phenylephrine increased accumbal dopamine levels 24 h after
reserpine. The black line represents the infusion time of phenyleph-
rine (40 min). *Significant increase compared to control (Student’s t
tests)
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RES did not affect the ability of PE to increase the
amount of accumbal dopamine (Fig. 4). In fact, the PE-
induced dopamine increase in the RES-treated rats was
identical to the PE-induced dopamine increase that was
observed in the control rats treated with the solvent of RES
(Fig. 4 versus Fig. 2). These data demonstrate that PE
acted at presynaptic alpha-adrenoceptors in these rats and
that RES did not change the state of postsynaptic alpha-
adrenoceptors. Previous studies have provided evidence
that alpha-adrenoceptors control the release of dopamine
from RES-sensitive dopamine pools (Cools and Verheij
2002; see also Verheij and Cools 2008). The present
finding that PE still increased dopamine in RES-treated HR
can be ascribed to the fact that the applied dose of RES did
not completely empty the dopaminergic storage vesicles in
this type of rat (see Verheij et al. 2008). One could argue
that the dose of 1 mg/kg of RES was too low to result in
more sensitive postsynaptic adrenoceptors. This explana-
tion is quite unlikely because the applied dose of 1 mg/kg
of RES strongly increased the sensitivity of the postsyn-
aptic beta-adrenoceptors in the nucleus accumbens of HR
(Verheij and Cools submitted). The increase of the sensi-
tivity of these beta-adrenoceptors can be explained by the
well-known action of RES to decreases accumbal nor-
adrenaline levels (Pan et al. 1993). The notion that the
noradrenaline that acts at accumbal alpha-adrenoceptors is
not influenced by RES (Fig. 4), whereas the noradrenaline
that acts at accumbal beta-adrenoceptors is affected by this
drug (Verheij and Cools submitted) demonstrates that RES-
induced changes in the overall amount of accumbal nor-
adrenaline do not reflect the processes that actually take
place at each distinct type of accumbal adrenoceptor.
Measuring adrenoceptor-specific changes in accumbal
dopamine have previously been found to be a valid and
reliable method for reaching conclusions about the norad-
renergic activity at the level of one single type of accumbal
adrenoceptor (Tuinstra and Cools 2000a). It is evident that
for the present study, measuring adrenoceptor-specific
changes in accumbal dopamine levels is preferred above
measuring changes in the total amount of accumbal nor-
adrenaline. On the basis of the results obtained by this
method, we hypothesize that the pools that contribute to the
release of noradrenaline at postsynaptic alpha-adrenocep-
tors of the nucleus accumbens are relatively insensitive to
RES. The concept of a RES-resistant compartment of
noradrenaline has also been suggested by others (Kopin
1964; Van Orden et al. 1970; Enna and Shore 1974;
Schwab and Thoenen 1983; Yamazaki et al. 1997). Our
data suggest that the compartment that releases noradren-
aline at postsynaptic alpha-adrenoceptors in the nucleus
accumbens contains AMPT-sensitive and newly synthe-
sized neurotransmitter that is not accumulated in RES-
sensitive vesicles. It remains to be investigated whether this
noradrenergic compartment consists of RES-resistant
cytoplasmatic pools or RES-insensitive vesicles.
The data provide direct evidence for the previously
reported hypothesis that AMPT can directly (by inhibiting
dopamine synthesis) and indirectly (by inhibiting nor-
adrenaline synthesis) change accumbal dopamine levels
(Saigusa et al. 1999). The present findings reveal that
compounds that directly or indirectly interact with ac-
cumbal alpha-adrenergic mechanisms should be considered
as agents that can have important therapeutic effects in
patients suffering from diseases in which accumbal dopa-
mine is known to be involved. In this respect, it is
important to mention that alpha-adrenergic agents have
indeed been found to exert therapeutic effects in animal
models of Parkinson’s disease (Haapalinna et al. 2003) and
addiction (Erb et al. 2000). Moreover, noradrenergic agents
may also be used to treat patients with attention deficit
hyperactivity disorder, schizophrenia and depression (Zhou
2004; Buitelaar et al. 2007). This aspect is elaborated in
detail elsewhere (Aono et al. 2007; Ikeda et al. 2007; for
review see Verheij and Cools 2008).
Finally, it is important to realize that the direct and
indirect therapeutic effects of noradrenergic agents
strongly depend on the amount of endogenous noradrena-
line in the synapse. In fact, the present study indicates that
a noradrenergic agonist may have postsynaptic effects in
individuals with low levels of endogenous noradrenaline,
whereas the same agonist may have presynaptic effects in
individuals with high levels of this neurotransmitter.
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